When your metaobolism slows down
This section is aimed primarily at investors and stock holders.
Trust Jimmy Kimmel to at least get a fair hearing of a Bill
This section is aimed primarily at Healthcare providers as well as inv...
Follow this link to MedPage for information on a Triple Combo of drugs for Hepatitis C https://www.medpagetoday.com/gastroenterology/hepatitis/65708
A combination of three drugs that act directly to block hepatitis C (HCV) replication successfully cured most patients who had previously failed therapy with such agents, researchers reported.
In two phase III trials, the investigational combination of sofosbuvir, velpatasvir, and voxilaprevir cleared the virus in 96% and 98% of patients, regardless of whether they had compensated cirrhosis or not, according to Marc
Adverse events associate with the combination were mild and similar to those seen among patients getting a placebo or the approved combination of sofosbuvir and velpatasvir (Epclusa), Bourlière and colleagues reported in the June 1 issue of the New England Journal of Medicine.
While retreatment options are available for patients with chronic HCV who have failed previous treatment with an interferon-containing regimen, there is no approved treatment for those whose treatment with direct-acting antiviral agents (DAAs) was unsuccessful.
Although the DAA regimens are highly effective, with cure rates in many cases of more than 95%, the sheer number of people with chronic HCV -- estimated to be some 150 million around the world -- means that a substantial number will fail therapy and need retreatment.
To help fill the gap, Bourlière and colleagues tested the three-drug combination in two trials -- dubbed POLARIS-1 and POLARIS-4 -- whose central difference was that patients in POLARIS-1 had failed therapy with an NS5A inhibitor, while those in POLARIS-4 had unsuccessful treatment with DAAs attacking other viral targets.